Phenotypes associated with this allele

• Allele Symbol: Il1b^tm1Lvp
• Allele Name: targeted mutation 1, Lex H T Van der Ploeg
• Allele ID: MGI:2157795
• Summary: 4 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Il1b^tm1Lvp/Il1b^tm1Lvp	129S7/SvEvBrd-Il1b^tm1Lvp	MGI:5085872
hm2	Il1b^tm1Lvp/Il1b^tm1Lvp	involves: 129S7/SvEvBrd	MGI:4839911
hm3	Il1b^tm1Lvp/Il1b^tm1Lvp	involves: 129S7/SvEvBrd * C57BL/6	MGI:4360483
hm4	Il1b^tm1Lvp/Il1b^tm1Lvp	involves: 129S7/SvEvBrd * C57BL/6 * C57BL/10 * RIIIS	MGI:4839923

Genotype
MGI:5085872

hm1

• Allelic Composition: Il1b^tm1Lvp/Il1b^tm1Lvp
• Genetic Background: 129S7/SvEvBrd-Il1b^tm1Lvp

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

immune system

immune system phenotype ( J:173245 )

N • mice co-housed with wild-type mice do not affect the susceptibility to induced colitis of wild-type mice

Genotype
MGI:4839911

hm2

• Allelic Composition: Il1b^tm1Lvp/Il1b^tm1Lvp
• Genetic Background: involves: 129S7/SvEvBrd

mortality/aging

increased susceptibility to bacterial infection induced morbidity/mortality ( J:136368 )

• following infection with Sterne 34F2 strain of Bacillus anthracis

decreased susceptibility to Togaviridae infection induced morbidity/mortality ( J:52841 )

• following Sindbis virus infection, 4% of mice die compared with 88% of similarly treated wild-type mice

decreased susceptibility to induced morbidity/mortality ( J:59893 , J:82394 )

• only 3 of 16 mice injected with B16M cells die after 12 days compared to all similarly treated wild-type mice (J:59893)

• following injection of B16 melanoma cells (J:82394)

immune system

abnormal macrophage physiology ( J:136368 )

• macrophages exhibit impaired ability to kill Bacillus anthracis compared with wild-type cells

decreased interleukin-1 beta secretion ( J:136368 )

• following exposure of macrophages to LPS or Bacillus anthracis spores

decreased tumor necrosis factor secretion ( J:82394 )

• from macrophages co-cultured with B16 cells

increased susceptibility to bacterial infection induced morbidity/mortality ( J:136368 )

• following infection with Sterne 34F2 strain of Bacillus anthracis

decreased susceptibility to viral infection ( J:135243 )

• neuroadapted Sindbis virus-infected mice exhibit attenuated hind limb paralysis and spinal cord motor neuron degeneration compared with similarly treated wild-type mice

decreased susceptibility to Togaviridae infection ( J:52841 )

• mice infected with Sindbis virus exhibit altered viral spread and reduced severe paralysis and death compared with similarly treated wild-type mice

• however, apoptosis and lesions in the brain following infection are the same as in wild-type mice

decreased susceptibility to Togaviridae infection induced morbidity/mortality ( J:52841 )

• following Sindbis virus infection, 4% of mice die compared with 88% of similarly treated wild-type mice

neoplasm

abnormal tumor vascularization ( J:82394 )

• angiogenesis in mice injected with B16 melanoma cells is nearly absent compared to in similarly treated wild-type mice

decreased metastatic potential ( J:59893 , J:82394 )

• mice injected with B16 cells exhibit reduced metastasis (by volume and density) in the liver compared with similarly treated wild-type mice (J:59893)

• mice injected with B16 cells exhibit decreased metastasis volume, an indicator of metastatic growth, compared with similarly treated wild-type mice (J:59893)

• following injection of B16 melanoma cells, no metastatic tumors are observed unlike in similarly treated wild-type mice (J:82394)

• mice injected with mammary cancer tumor DA/3 exhibit slower and smaller tumor development compared with similarly treated wild-type mice (J:82394)

decreased tumor growth/size ( J:59893 , J:82394 )

• mice injected with B16 cells exhibit decreased metastasis volume, an indicator of metastatic growth, compared with similarly treated wild-type mice (J:59893)

• mice injected with mammary cancer tumor DA/3 exhibit slower and smaller tumor development compared with similarly treated wild-type mice (J:82394)

cardiovascular system

abnormal tumor vascularization ( J:82394 )

• angiogenesis in mice injected with B16 melanoma cells is nearly absent compared to in similarly treated wild-type mice

homeostasis/metabolism

decreased susceptibility to injury ( J:128238 )

• following arterial ligation, mice exhibit reduced and smaller cerebral aneurysm with reduced ssDNA and TUNEL+ cells in the vascular walls compared with similarly treated wild-type mice

hematopoietic system

abnormal macrophage physiology ( J:136368 )

• macrophages exhibit impaired ability to kill Bacillus anthracis compared with wild-type cells

Genotype
MGI:4360483

hm3

• Allelic Composition: Il1b^tm1Lvp/Il1b^tm1Lvp
• Genetic Background: involves: 129S7/SvEvBrd * C57BL/6

mortality/aging

decreased susceptibility to induced morbidity/mortality ( J:67001 )

• following acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis

immune system

abnormal lymphocyte physiology ( J:67001 )

• following acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis, popliteal and inguinal lymph node mononuclear cell proliferation is reduced compared to in similarly treated wild-type mice

• however, anti-CD3-induced T cell proliferation is normal

decreased circulating interleukin-1 beta level ( J:27234 )

• mice fail to produce IL-1 beta at a basal level or in response to LPS administration

decreased interferon-gamma secretion ( J:67001 )

• following acetylcholine receptor-stimulation of popliteal and inguinal lymph node mononuclear cells

decreased interleukin-2 secretion ( J:67001 )

• following acetylcholine receptor-stimulation of popliteal and inguinal lymph node mononuclear cells

decreased interleukin-4 secretion ( J:67001 )

• following acetylcholine receptor-stimulation of popliteal and inguinal lymph node mononuclear cells

abnormal interleukin-6 secretion ( J:27234 )

• mice fail to increase plasma levels of IL-6 in response to the turpentine injection

• in contrast, control mice have a peak of plasma IL-6 levels about 10-fold above basal 8 hours after injection with levels remaining above basal for at least 96 hours post-injection

decreased susceptibility to experimental autoimmune myasthenia gravis ( J:67001 )

• mice are resistant to acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis (decreased mortality, muscle weakness, lymphocyte proliferation, Th1 and Th2 cytokine production, and serum acetylcholine receptor antibodies) compared with similarly treated wild-type mice

decreased inflammatory response ( J:27234 )

• some of the long-term side effects of the inflammatory response to turpentine does not occur in these mice

• these side effects include loss of weight, decrease food and water intake

• influx of white blood cells to the injection site occurs in a manner similar to wild-type mice

decreased acute inflammation ( J:27234 )

• mice fail to develop a fever in response to the inflammatory agent turpentine

• mice also fail to increase plasma levels of IL-6 in response to the turpentine injection

• there is a 2- to 5- fold reduction in mRNA transcripts for acute-phase proteins after 8- to 72 hours after turpentine injection

homeostasis/metabolism

decreased circulating interleukin-1 beta level ( J:27234 )

• mice fail to produce IL-1 beta at a basal level or in response to LPS administration

impaired febrile response ( J:27234 )

• mice fail to develop a fever in response to the inflammatory agent turpentine

• in contrast, mice develop a fever starting 5 hours after administration that lasts for 24 hours

• control mice also have a decrease in locomotor activity the night after injection while mutant mice have normal activity

hematopoietic system

abnormal lymphocyte physiology ( J:67001 )

• following acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis, popliteal and inguinal lymph node mononuclear cell proliferation is reduced compared to in similarly treated wild-type mice

• however, anti-CD3-induced T cell proliferation is normal

Genotype
MGI:4839923

hm4

• Allelic Composition: Il1b^tm1Lvp/Il1b^tm1Lvp
• Genetic Background: involves: 129S7/SvEvBrd * C57BL/6 * C57BL/10 * RIIIS

nervous system

abnormal blood-brain barrier function ( J:105009 )

• following corticectomy injury, mice exhibit delayed re-establishment of the blood-brain barrier compared with similarly treated wild-type mice

homeostasis/metabolism

decreased susceptibility to injury ( J:105009 )

• following corticectomy injury, mice exhibit reduced GFAP immunoreactivity and delayed re-establishment of the blood-brain barrier compared with similarly treated wild-type mice until day 5

cardiovascular system

abnormal blood-brain barrier function ( J:105009 )

• following corticectomy injury, mice exhibit delayed re-establishment of the blood-brain barrier compared with similarly treated wild-type mice